Vinayak G. Wagaskar, MBBS, shares potential explanations for the “obesity paradox”—improved survival outcomes in patients with a high body mass index (BMI)—in patients with metastatic castration-resistant prostate cancer (mCRPC). A study presented at the 2021 European Association of Urology showed improved survival outcomes in obese patients with mCRPC compared with overweight and normal weight patients. In the video also discusses next steps with this research.
Wagaskar is an instructor of urology at Mount Sinai in New York City
Study evaluates polygenic risk score for prostate cancer risk prediction
March 18th 2023“Vanderbilt researchers are participating in numerous projects related to PRS and disease risk; studies such as this highlight the importance of evaluating whether novel clinical tools actually enhance care,” said Kerry Schaffer, MD.
Rise in prostate cancer observed after USPSTF recommendation against screening
March 15th 2023"The government is spending more in Medicare, we are getting more people with prostate cancer, more deaths with prostate cancer, [and] more metastasis with prostate cancer. While it is so simple: today, PSA is still there," says Navin Shah, MD, MS, FACS, FICS, FACIP.
2 Clarke Drive
Cranbury, NJ 08512